Heart Failure in the Twenty-First Century: Is it a Coronary Artery Disease or Hypertension Problem?

Cardiology Clinics

Volumn 25, Issue 4, 2007, Pages 487-495

  Velagaleti, Raghava S ^a   Vasan, Ramachandran S ^a,b  

^a FRAMINGHAM HEART STUDY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; ATHEROGENIC DIET; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE COURSE; GENDER; HEART FAILURE; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; INCIDENCE; LIFESTYLE; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; RACE; REVIEW;

COMORBIDITY; CORONARY DISEASE; DISEASE PROGRESSION; HEART FAILURE; HUMANS; HYPERTENSION; MYOCARDIAL REVASCULARIZATION; OBESITY; RISK FACTORS;

EID: 36549042926     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2007.08.010     Document Type: Review

References (98)

1. Executive summary. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 12 1 (2006) 10-38
2. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 12 (2005) e154-e235
3. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 5 (2007) e69-e171
4. Lloyd-Jones D.M., Larson M.G., Leip E.P., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106 24 (2002) 3068-3072
5. Owan T.E., and Redfield M.M. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 47 5 (2005) 320-332
6. O'Connell J.B., and Bristow M.R. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 13 4 (1994) S107-S112
7. Ho K.K., Anderson K.M., Kannel W.B., et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88 1 (1993) 107-115
8. Levy D., Kenchaiah S., Larson M.G., et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347 18 (2002) 1397-1402
9. Kenchaiah S., Narula J., and Vasan R.S. Risk factors for heart failure. Med Clin North Am 88 5 (2004) 1145-1172
10. Kenchaiah S., Evans J.C., Levy D., et al. Obesity and the risk of heart failure. N Engl J Med 347 5 (2002) 305-313
11. Maron B.J., Towbin J.A., Thiene G., et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113 14 (2006) 1807-1816
12. Gillum R.F. Epidemiology of heart failure in the United States. Am Heart J 126 4 (1993) 1042-1047
13. McKee P.A., Castelli W.P., McNamara P.M., et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med 285 26 (1971) 1441-1446
14. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 22 (2001) 1651-1658
15. Bourassa M.G., Gurne O., Bangdiwala S.I., et al. Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol 22 4 Suppl A (1993) 14A-19A
16. Torp-Pedersen C., Moller M., Bloch-Thomsen P.E., et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 341 12 (1999) 857-865
17. Kavey R.E., Daniels S.R., Lauer R.M., et al. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 107 11 (2003) 1562-1566
18. Tuzcu E.M., Kapadia S.R., Tutar E., et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 103 22 (2001) 2705-2710
19. Mohri M., and Takeshita A. Coronary microvascular disease in humans. Jpn Heart J 40 2 (1999) 97-108
20. Poulsen S.H., Jensen S.E., and Egstrup K. Longitudinal changes and prognostic implications of left ventricular diastolic function in first acute myocardial infarction. Am Heart J 137 5 (1999) 910-918
21. Humphrey L.S., Topol E.J., Rosenfeld G.I., et al. Immediate enhancement of left ventricular relaxation by coronary artery bypass grafting: intraoperative assessment. Circulation 77 4 (1988) 886-896
22. Bonow R.O., Vitale D.F., Bacharach S.L., et al. Asynchronous left ventricular regional function and impaired global diastolic filling in patients with coronary artery disease: reversal after coronary angioplasty. Circulation 71 2 (1985) 297-307
23. Hochman J.S., Boland J., Sleeper L.A., et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. SHOCK Registry Investigators. Circulation 91 3 (1995) 873-881
24. Lavie C.J., and Gersh B.J. Mechanical and electrical complications of acute myocardial infarction. Mayo Clin Proc 65 5 (1990) 709-730
25. Sutton M.G., and Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101 25 (2000) 2981-2988
26. Wijns W., Vatner S.F., and Camici P.G. Hibernating myocardium. N Engl J Med 339 3 (1998) 173-181
27. Kloner R.A., and Przyklenk K. Hibernation and stunning of the myocardium. N Engl J Med 325 26 (1991) 1877-1879
28. Bolli R. Myocardial 'stunning' in man. Circulation 86 6 (1992) 1671-1691
29. Auerbach M.A., Schoder H., Hoh C., et al. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation 99 22 (1999) 2921-2926
30. Wei L., Kadoya M., Momose M., et al. Serial assessment of left ventricular function in various patient groups with Tl-201 gated myocardial perfusion SPECT. Radiat Med 25 2 (2007) 65-72
31. Bell S.P., Fabian J., Watkins M.W., et al. Decrease in forces responsible for diastolic suction during acute coronary occlusion. Circulation 96 7 (1997) 2348-2352
32. Firstenberg M.S., Smedira N.G., Greenberg N.L., et al. Relationship between early diastolic intraventricular pressure gradients, an index of elastic recoil, and improvements in systolic and diastolic function. Circulation 104 12 Suppl 1 (2001) I330-I335
33. Uren N.G., Melin J.A., De Bruyne B., et al. Relation between myocardial blood flow and the severity of coronary-artery stenosis. N Engl J Med 330 25 (1994) 1782-1788
34. Di Carli M., Czernin J., Hoh C.K., et al. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation 91 7 (1995) 1944-1951
35. Cowie M.R., Wood D.A., Coats A.J., et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J 20 6 (1999) 421-428
36. Gheorghiade M., and Bonow R.O. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 97 3 (1998) 282-289
37. Levy D., Larson M.G., Vasan R.S., et al. The progression from hypertension to congestive heart failure. JAMA 275 20 (1996) 1557-1562
38. Uretsky B.F., Thygesen K., Armstrong P.W., et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 102 6 (2000) 611-616
39. Repetto A., Dal Bello B., Pasotti M., et al. Coronary atherosclerosis in end-stage idiopathic dilated cardiomyopathy: an innocent bystander?. Eur Heart J 26 15 (2005) 1519-1527
40. Felker G.M., Thompson R.E., Hare J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342 15 (2000) 1077-1084
41. Hedrich O., Jacob M., and Hauptman P.J. Progression of coronary artery disease in non-ischemic dilated cardiomyopathy. Coron Artery Dis 15 5 (2004) 291-297
42. Graf S., Khorsand A., Gwechenberger M., et al. Typical chest pain and normal coronary angiogram: cardiac risk factor analysis versus PET for detection of microvascular disease. J Nucl Med 48 2 (2007) 175-181
43. Qian J.Y., Ge J.B., Fan B., et al. Identification of syndrome X using intravascular ultrasound imaging and Doppler flow mapping. Chin Med J (Engl) 117 4 (2004) 521-527
44. Bart B.A., Shaw L.K., McCants Jr. C.B., et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 30 4 (1997) 1002-1008
45. Felker G.M., Shaw L.K., and O'Connor C.M. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 39 2 (2002) 210-218
46. Purek L., Laule-Kilian K., Christ A., et al. Coronary artery disease and outcome in acute congestive heart failure. Heart 92 5 (2006) 598-602
47. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 7 (2001) 494-502
48. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327 10 (1992) 669-677
49. Yusuf S., Pepine C.J., Garces C., et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 340 8829 (1992) 1173-1178
50. Pitt B., White H., Nicolau J., et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46 3 (2005) 425-431
51. Janosi A., Ghali J.K., Herlitz J., et al. Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF. Am Heart J 146 4 (2003) 721-728
52. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 342 8875 (1993) 821-828
53. O'Connor C.M., Velazquez E.J., Gardner L.H., et al. Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank). Am J Cardiol 90 2 (2002) 101-107
54. Alderman E.L., Fisher L.D., Litwin P., et al. Results of coronary artery surgery in patients with poor left ventricular function (CASS). Circulation 68 4 (1983) 785-795
55. Baker D.W., Jones R., Hodges J., et al. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA 272 19 (1994) 1528-1534
56. Pigott J.D., Kouchoukos N.T., Oberman A., et al. Late results of surgical and medical therapy for patients with coronary artery disease and depressed left ventricular function. J Am Coll Cardiol 5 5 (1985) 1036-1045
57. Elefteriades J.A., Tolis Jr. G., Levi E., et al. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol 22 5 (1993) 1411-1417
58. Kannel W.B., Gordon T., and Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 71 1 (1969) 89-105
59. Kannel W.B., Dannenberg A.L., and Levy D. Population implications of electrocardiographic left ventricular hypertrophy. Am J Cardiol 60 17 (1987) 85I-93I
60. Levy D., Anderson K.M., Savage D.D., et al. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 108 1 (1988) 7-13
61. Urbina E.M., Gidding S.S., Bao W., et al. Effect of body size, ponderosity, and blood pressure on left ventricular growth in children and young adults in the Bogalusa Heart Study. Circulation 91 9 (1995) 2400-2406
62. Inouye I., Massie B., Loge D., et al. Abnormal left ventricular filling: an early finding in mild to moderate systemic hypertension. Am J Cardiol 53 1 (1984) 120-126
63. Smith V.E., Schulman P., Karimeddini M.K., et al. Rapid ventricular filling in left ventricular hypertrophy: II. Pathologic hypertrophy. J Am Coll Cardiol 5 4 (1985) 869-874
64. Pearson A.C., Gudipati C., Nagelhout D., et al. Echocardiographic evaluation of cardiac structure and function in elderly subjects with isolated systolic hypertension. J Am Coll Cardiol 17 2 (1991) 422-430
65. Devereux R.B. Left ventricular diastolic dysfunction: early diastolic relaxation and late diastolic compliance. J Am Coll Cardiol 13 2 (1989) 337-339
66. Brucks S., Little W.C., Chao T., et al. Contribution of left ventricular diastolic dysfunction to heart failure regardless of ejection fraction. Am J Cardiol 95 5 (2005) 603-606
67. Marcus M.L., Harrison D.G., Chilian W.M., et al. Alterations in the coronary circulation in hypertrophied ventricles. Circulation 75 1 Pt 2 (1987) I19-I25
68. Gandhi S.K., Powers J.C., Nomeir A.M., et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 344 1 (2001) 17-22
69. Gheorghiade M., Zannad F., Sopko G., et al. Acute heart failure syndromes: current state and framework for future research. Circulation 112 25 (2005) 3958-3968
70. Vasan R.S., Larson M.G., Leip E.P., et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 345 18 (2001) 1291-1297
71. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 6 (2003) 1206-1252
72. Flegal K.M., Carroll M.D., Ogden C.L., et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 14 (2002) 1723-1727
73. Kostis J.B., Davis B.R., Cutler J., et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 278 3 (1997) 212-216
74. Dahlof B., Lindholm L.H., Hansson L., et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 338 8778 (1991) 1281-1285
75. Moser M., and Hebert P.R. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 27 5 (1996) 1214-1218
76. Vasan R.S., and Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med 156 16 (1996) 1789-1796
77. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 3 (2000) 145-153
78. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 327 10 (1992) 685-691
79. Mathew J., Sleight P., Lonn E., et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104 14 (2001) 1615-1621
80. Ingelsson E., Bjorklund-Bodegard K., Lind L., et al. Diurnal blood pressure pattern and risk of congestive heart failure. JAMA 295 24 (2006) 2859-2866
81. Vasan R.S., Beiser A., Seshadri S., et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 287 8 (2002) 1003-1010
82. Staessen J.A., Gasowski J., Wang J.G., et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355 9207 (2000) 865-872
83. Stamler J., Stamler R., and Neaton J.D. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 153 5 (1993) 598-615
84. Brush Jr. J.E., Cannon III R.O., Schenke W.H., et al. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med 319 20 (1988) 1302-1307
85. Bache R.J., Arentzen C.E., Simon A.B., et al. Abnormalities in myocardial perfusion during tachycardia in dogs with left ventricular hypertrophy: metabolic evidence for myocardial ischemia. Circulation 69 2 (1984) 409-417
86. Zhang J., Merkle H., Hendrich K., et al. Bioenergetic abnormalities associated with severe left ventricular hypertrophy. J Clin Invest 92 2 (1993) 993-1003
87. Falk E., Shah P.K., and Fuster V. Coronary plaque disruption. Circulation 92 3 (1995) 657-671
88. Giannattasio C., Mangoni A.A., Failla M., et al. Impaired radial artery compliance in normotensive subjects with familial hypercholesterolemia. Atherosclerosis 124 2 (1996) 249-260
89. van der Linde N.A., Sijbrands E.J., Boomsma F., et al. Effect of low-density lipoprotein cholesterol on angiotensin II sensitivity: a randomized trial with fluvastatin. Hypertension 47 6 (2006) 1125-1130
90. Leibovitz E., Beniashvili M., Zimlichman R., et al. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am J Hypertens 16 9 Pt 1 (2003) 715-718
91. Egashira K., Hirooka Y., Kai H., et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89 6 (1994) 2519-2524
92. Vasan R.S., Evans J.C., Larson M.G., et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351 1 (2004) 33-41
93. Newton-Cheh C., Guo C.Y., Gona P., et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 49 4 (2007) 846-856
94. Kathiresan S., Larson M.G., Benjamin E.J., et al. Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am J Hypertens 18 5 Pt 1 (2005) 657-665
95. Kathiresan S., Gona P., Larson M.G., et al. Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation 113 7 (2006) 938-945
96. Wang T.J., Gona P., Larson M.G., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355 25 (2006) 2631-2639
97. Yusuf S., Reddy S., Ounpuu S., et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 104 22 (2001) 2746-2753
98. Kannel W.B. Lessons from curbing the coronary artery disease epidemic for confronting the impending epidemic of heart failure. Med Clin North Am 88 5 (2004) 1129-1133 ix